Startseite>>Signaling Pathways>> Others>>(R)-MK-5046

(R)-MK-5046

Katalog-Nr.GC70870

(R)-MK-5046 ist das Isomer von MK-5046 und kann als experimentelle Kontrolle verwendet werden.

Products are for research use only. Not for human use. We do not sell to patients.

(R)-MK-5046 Chemische Struktur

Cas No.: 1021736-25-3

Größe Preis Lagerbestand Menge
1 mg
63,00 $
Auf Lager
5 mg
135,00 $
Auf Lager
10 mg
216,00 $
Auf Lager
25 mg
396,00 $
Auf Lager
50 mg
594,00 $
Auf Lager
100 mg
891,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
(R)-MK-5046 is the isomer of MK-5046 , and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity.

References:
[1]. Guan XM, et al. Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist. J Pharmacol Exp Ther. 2011 Feb;336(2):356-364.
[2]. Sebhat IK, et al. Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity. ACS Med Chem Lett. 2010 Oct 18;2(1):43-47.
[3]. Ramos-Alvarez I, et al. The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3. J Pharmacol Exp Ther. 2022 Aug;382(2):66-78.

Bewertungen

Review for (R)-MK-5046

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (R)-MK-5046

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.